2023
Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association
Cohen J, Brown N, Brown S, Dent S, van Dorst D, Herrmann S, Lang N, Oudit G, Touyz R, Arteriosclerosis T. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2023, 80: e46-e57. PMID: 36621810, PMCID: PMC10602651, DOI: 10.1161/hyp.0000000000000224.Peer-Reviewed Original ResearchConceptsCardiovascular toxicityVascular endothelial growth factor inhibitorsCancer therapyEvidence-based clinical trialsNational hypertension guidelinesVascular endothelial growth factor receptorCardiovascular risk factorsDiscontinuation of treatmentCommon side effectsGrowth factor inhibitorsEndothelial growth factor receptorPrimary care professionalsAmerican Heart AssociationTyrosine kinase inhibitorsOptimal therapeutic effectNitric oxide generationGrowth factor receptorHypertension specialistsHypertension guidelinesSympathetic outflowAdjunctive therapyCardiovascular mortalityEndothelial dysfunctionHormone therapyBlood pressure
2022
Comparison of Pharmacy Refill Data With Chemical Adherence Testing in Assessing Medication Nonadherence in a Safety Net Hospital Setting
Osula D, Wu B, Schesing K, Das SR, Moss E, Alvarez K, Clark C, Halm EA, Brown NJ, Vongpatanasin W. Comparison of Pharmacy Refill Data With Chemical Adherence Testing in Assessing Medication Nonadherence in a Safety Net Hospital Setting. Journal Of The American Heart Association 2022, 11: e027099. PMID: 36193931, PMCID: PMC9673714, DOI: 10.1161/jaha.122.027099.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersCross-Sectional StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionMedication AdherencePharmacySafety-net ProvidersSodium Chloride Symporter InhibitorsConceptsEnzyme inhibitors/angiotensin receptor blockersAngiotensin receptor blockersCalcium channel blockersReceptor blockersPositive predictive valueUncontrolled hypertensionBeta blockersMedication nonadherenceAntihypertensive drugsDrug classesChannel blockersAngiotensin-converting enzyme inhibitors/angiotensin receptor blockersPredictive valueAdherence testingSafety-net hospital settingSafety-net health systemLow positive predictive valuePharmacy refill dataProportion of daysCross-sectional studyPlasma drug levelsDiagnostic test characteristicsPharmacy fill dataCommon cardiovascular drugsRefill data
2021
Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program
Akwo EA, Robinson-Cohen C, Chung CP, Shah SC, Brown NJ, Ikizler TA, Wilson OD, Rowan BX, Shuey MM, Siew ED, Luther JM, Giri A, Hellwege JN, Edwards D, Roumie CL, Tao R, Tsao PS, Gaziano JM, Wilson PWF, O’Donnell C, Edwards TL, Kovesdy CP, Hung AM, Program O. Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. Hypertension 2021, 78: 376-386. PMID: 34148359, PMCID: PMC8364328, DOI: 10.1161/hypertensionaha.120.16181.Peer-Reviewed Original ResearchTreatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids
Luther JM, Wei DS, Ghoshal K, Peng D, Adler GK, Turcu AF, Nian H, Yu C, Solorzano CC, Pozzi A, Brown NJ. Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids. Hypertension 2021, 77: 1323-1331. PMID: 33583202, PMCID: PMC8320355, DOI: 10.1161/hypertensionaha.120.14808.Peer-Reviewed Original ResearchConnecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan
Watts SW, Alexander BT, Baylis C, Brown NJ, Cassis LA, Denton KM, Joe B, Lerman LO, Oparil S, Reckelhoff JF, Sandberg K, Touyz RM. Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan. Hypertension 2021, 77: 296-307. PMID: 33390045, PMCID: PMC7856247, DOI: 10.1161/hypertensionaha.120.16623.Peer-Reviewed Original Research
2020
Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data
Shuey M, Perkins B, Nian H, Yu C, Luther JM, Brown N. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. BMJ Open 2020, 10: e033100. PMID: 32461291, PMCID: PMC7259833, DOI: 10.1136/bmjopen-2019-033100.Peer-Reviewed Original ResearchConceptsBody mass indexHigher body mass indexElectronic medical recordsBaseline systolic BPTherapy-resistant hypertensionBlood pressure responseRetrospective cohort studyDiastolic BPSystolic BPBP responseBaseline BPCohort studyChronic kidney disease stage 3Real-world clinical settingElectronic medical record dataMean systolic BPDisease stage 3Glomerular filtration rateIschemic heart diseasePressure responseMedical record dataClinical trial dataHigh-density lipoproteinLow-density lipoproteinAcademic medical center
2018
Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study
Shuey MM, Gandelman JS, Chung CP, Nian H, Yu C, Denny JC, Brown NJ. Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study. BMJ Open 2018, 8: e021640. PMID: 29950471, PMCID: PMC6020960, DOI: 10.1136/bmjopen-2018-021640.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAgedAngiotensin Receptor AntagonistsAntihypertensive AgentsBlack or African AmericanBlood PressureCalcium Channel BlockersCase-Control StudiesDiabetes Mellitus, Type 2Electronic Health RecordsFemaleHumansHypertensionLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrevalenceTennesseeWhite PeopleConceptsElectronic health recordsResistant hypertensionBlood pressureChronic kidney disease stage 3Mineralocorticoid receptor antagonist useClinical treatmentDihydropyridine calcium channel blockerAntihypertensive medication classesControlled blood pressureOutpatient blood pressureTotal hypertensive populationAngiotensin receptor blockersTransient ischemic attackDisease stage 3Health recordsMineralocorticoid receptor antagonistsReceptor antagonist useHigh blood pressureIschemic heart diseaseAlpha-2 agonistsBody mass indexCalcium channel blockersAfrican American patientsNumber of patientsType 2 diabetes
2017
Systolic Blood Pressure and Biochemical Assessment of Adherence
McNaughton CD, Brown NJ, Rothman RL, Liu D, Kabagambe EK, Levy PD, Self WH, Storrow AB, Collins SP, Roumie CL. Systolic Blood Pressure and Biochemical Assessment of Adherence. Hypertension 2017, 70: 307-314. PMID: 28652467, PMCID: PMC5531074, DOI: 10.1161/hypertensionaha.117.09659.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBiomarkersBlood PressureBlood Pressure DeterminationCross-Sectional StudiesEmergency Medical ServicesEmergency Service, HospitalFemaleHealth LiteracyHumansHypertensionMaleMass SpectrometryMedication AdherenceMedication Therapy ManagementMiddle AgedUnited StatesConceptsElevated blood pressureSystolic blood pressureBlood pressureSystolic BPEmergency departmentBiochemical assessmentAntihypertensive adherenceAdherent patientsLower systolic blood pressureAntihypertensive medication adherenceHigher systolic BPPrimary care providersBody mass indexCross-sectional studyAntihypertensive nonadherenceNonadherent patientsPrimary outcomeED careMedication nonadherenceMass indexMedication adherenceAcademic hospitalCare providersAntihypertensivesBlood assays
2016
Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study
Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Poku KA, Brown NJ, Moore JH, Williams SM. Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. PLOS ONE 2016, 11: e0162753. PMID: 27732601, PMCID: PMC5061429, DOI: 10.1371/journal.pone.0162753.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBlood PressureBody Mass IndexCardiovascular DiseasesCholesterolCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGhanaHumansHypertensionMaleMiddle AgedObesityPlasminogen Activator Inhibitor 1PrevalenceRisk FactorsSmokingSurveys and QuestionnairesTissue Plasminogen ActivatorTriglyceridesUrbanizationYoung AdultConceptsCardiovascular disease risk factorsDisease risk factorsRisk factorsUrban residenceWorse cardiovascular risk profileCardiovascular risk profileRelated clinical outcomesPopulation-based surveyCross-sectional studyFibrinolytic markersTotal cholesterolCholesterol profileClinical outcomesLDL cholesterolCardiovascular diseaseBMI adjustmentHigh riskRural participantsRisk profileLarger studyT-PAUrban womenUrban menObesityCholesterolPlasminogen Activator Inhibitor‐1 and Diagnosis of the Metabolic Syndrome in a West African Population
Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Brown NJ, Moore JH, Williams SM. Plasminogen Activator Inhibitor‐1 and Diagnosis of the Metabolic Syndrome in a West African Population. Journal Of The American Heart Association 2016, 5: e003867. PMID: 27697752, PMCID: PMC5121488, DOI: 10.1161/jaha.116.003867.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntihypertensive AgentsBlood GlucoseBlood PressureBody Mass IndexCholesterol, HDLCross-Sectional StudiesDiabetes MellitusFastingFemaleGhanaHumansHypertensionHypoglycemic AgentsMaleMetabolic SyndromeMiddle AgedPlasminogen Activator Inhibitor 1PrevalenceRural PopulationTriglyceridesUrban PopulationYoung AdultConceptsPlasminogen activator inhibitor-1Activator inhibitor-1Metabolic syndromeRisk factorsDiagnostic criteriaLow high-density lipoproteinInhibitor-1Relevance of MetSAge-standardized prevalenceConventional risk factorsCardiovascular disease riskBody mass indexMetS diagnostic criteriaPAI-1 levelsHigh-density lipoproteinCross-sectional analysisMetS prevalenceIschemic eventsMetS componentsMetS criteriaWest African populationsMass indexPlasma levelsGhanaian menAntifibrinolytic factorsCombined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016, 133: 1115-1124. PMID: 26976916, PMCID: PMC4800749, DOI: 10.1161/circulationaha.115.018622.Peer-Reviewed Original ResearchMeSH KeywordsAbnormalities, Drug-InducedAminobutyratesAngioedemaAngiotensin Receptor AntagonistsBiphenyl CompoundsBradykininContraindicationsDrug CombinationsDrug CostsDrug SynergismEnalaprilEnzyme InhibitorsFemaleFollow-Up StudiesHeart FailureHumansHyperkalemiaHypertensionKidneyMulticenter Studies as TopicNatriuretic PeptidesNeprilysinPregnancyProdrugsProspective StudiesPyridinesRandomized Controlled Trials as TopicStroke VolumeTetrazolesThiazepinesValsartanConceptsValsartan/sacubitrilReduced ejection fractionHeart failureNatriuretic peptideEjection fractionN-terminal pro-brain natriuretic peptideNeprilysin inhibitor prodrug sacubitrilPro-brain natriuretic peptideAngiotensin receptor blocker valsartanAngiotensin receptor antagonismAngiotensin receptor blockersHeart Failure TrialReceptor blocker valsartanAngiotensin receptor antagonistsBrain natriuretic peptideOngoing clinical trialsMechanism of actionNeprilysin inhibitionAldosterone antagonistsAldosterone systemReceptor blockersBlood pressureFailure TrialPathophysiological mechanismsReceptor antagonism
2014
Hypertension Is Associated With Preamyloid Oligomers in Human Atrium: A Missing Link in Atrial Pathophysiology?
Sidorova TN, Mace LC, Wells KS, Yermalitskaya LV, Su P, Shyr Y, Atkinson JB, Fogo AB, Prinsen JK, Byrne JG, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Glabe CG, Brown NJ, Barnett JV, Murray KT. Hypertension Is Associated With Preamyloid Oligomers in Human Atrium: A Missing Link in Atrial Pathophysiology? Journal Of The American Heart Association 2014, 3: e001384. PMID: 25468655, PMCID: PMC4338732, DOI: 10.1161/jaha.114.001384.Peer-Reviewed Original ResearchConceptsAtrial samplesAtrial amyloidosisMitral valve replacement/repairValve replacement/repairCoronary Artery Bypass GraftingHuman atriumArtery Bypass GraftingElective cardiac surgeryAortic valve replacementPresence of hypertensionCongestive heart failureCoronary artery diseaseAtrial natriuretic peptideReplacement/repairAtrial pathophysiologyBypass GraftingClinical hypertensionMost patientsValve replacementArtery diseaseCardiac surgeryHeart failureNatriuretic peptideAtrial arrhythmiasMean ageGenetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans
Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. International Journal Of Cardiology Cardiovascular Risk And Prevention 2014, 8: 475-480. PMID: 25064769, PMCID: PMC4115247, DOI: 10.1016/j.jash.2014.04.011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlack or African AmericanBlood PressureCytochrome P-450 CYP4ACytochrome P-450 Enzyme SystemDNADouble-Blind MethodFemaleGenetic VariationGenotypeHumansHypertensionMaleMiddle AgedMineralocorticoid Receptor AntagonistsPilot ProjectsRadioimmunoassayUnited StatesYoung AdultConceptsBlood pressure responseBlood pressureReceptor antagonismPressure responseMineralocorticoid receptor antagonismSalt-sensitive hypertensionAfrican AmericansExploratory pilot studyGC individualsAldosterone responseResistant hypertensionAntihypertensive effectTreatment responsePrecluded analysisCC genotypeCC homozygotesSpironolactoneC alleleHypertensionPilot studyENaC activationCYP4A11AmilorideActivation of ENaC.ENaC inhibition
2012
Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake
Rao AD, Sun B, Saxena A, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, Williams JS. Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake. Journal Of Human Hypertension 2012, 27: 176-180. PMID: 22648267, PMCID: PMC3463709, DOI: 10.1038/jhh.2012.22.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersBlood PressureChi-Square DistributionEuropeFemaleGene FrequencyGenetic Predisposition to DiseaseHumansHypertensionImmediate-Early ProteinsLinear ModelsLinkage DisequilibriumLogistic ModelsMaleMiddle AgedPhenotypePolymorphism, Single NucleotideProtein Serine-Threonine KinasesReninRenin-Angiotensin SystemSodium Chloride, DietaryUnited StatesWhite PeopleConceptsDietary salt intakeBlood pressureSalt intakeSingle nucleotide polymorphismsHigher systolic blood pressureMeasurement of BPAldosterone system activityRAA system activitySystem activitySystolic blood pressureSalt-sensitive hypertensionSGK1 gene variantGlucocorticoid-inducible kinase 1Non-significant trendNormotensive populationRenin responseEpithelial sodium channelHuman hypertensionGenotype statusStudy populationDistal nephronHypertensionAdditive genetic modelSodium channelsGene variantsLysine-Specific Demethylase 1: An Epigenetic Regulator of Salt-Sensitive Hypertension
Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE, Raby BA, Adler GK, Hopkins PN, Brown NJ, Jeunemaitre X, Ferri C, Fang R, Leonor T, Cui J, Guo X, Taylor KD, Chen Y, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Shi Y. Lysine-Specific Demethylase 1: An Epigenetic Regulator of Salt-Sensitive Hypertension. American Journal Of Hypertension 2012, 25: 812-817. PMID: 22534796, PMCID: PMC3721725, DOI: 10.1038/ajh.2012.43.Peer-Reviewed Original ResearchConceptsMinor allele carriersSalt-sensitive hypertensionBlood pressureSingle nuclear polymorphismsAllele carriersHypertensive cohortDietary saltWT miceLiberal salt dietLiberal salt intakeSystolic blood pressureSerum aldosterone concentrationHeterozygote knockout miceTranslational research studiesRenovascular responsivenessAldosterone concentrationSalt dietDietary sodiumSalt intakeSystolic BPHuman studiesHypertensionKnockout miceClinical relevanceCaucasian cohort
2011
CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow
Williams JS, Hopkins PN, Jeunemaitre X, Brown NJ. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. Journal Of Hypertension 2011, 29: 1913-1918. PMID: 21873888, PMCID: PMC3309034, DOI: 10.1097/hjh.0b013e32834aa786.Peer-Reviewed Original ResearchConceptsMean arterial pressureHigh salt intakeRenal blood flowHypertensive individualsBlood pressureSalt intakeC alleleSalt restrictionNormotensive individualsBlood flowSalt-sensitive blood pressureSalt sensitivityLow-salt dietDiagnosis of hypertensionHigh blood pressureSalt-sensitive hypertensionRenal vasodilationPressor responseSalt dietArterial pressureAngiotensin IIAttenuated increaseSodium homeostasisCYP4A11 T8590C polymorphismHypertensionCombined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients
Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 2011, 80: 978-985. PMID: 21775975, PMCID: PMC3656595, DOI: 10.1038/ki.2011.228.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCardiovascular DiseasesDrug Therapy, CombinationFemaleHumansHypertensionKaplan-Meier EstimateKidney Failure, ChronicLogistic ModelsMaleMiddle AgedPropensity ScoreProportional Hazards ModelsRenal DialysisRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesConceptsAngiotensin receptor blockersAntihypertensive medicationsARB therapyCardiovascular deathChronic hemodialysisCardiovascular mortalityHazard ratioHemodialysis patientsRisk factorsBaseline cardiovascular risk factorsAngiotensin-converting enzyme inhibitionLarge dialysis providerCardiovascular risk factorsChronic hemodialysis patientsKaplan-Meier methodMortality hazard ratioAntihypertensive therapyReceptor blockersAntihypertensive agentsCox regressionCerebrovascular mortalityClinical trialsTreatment weightingObservational studyACEIThe Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians
Vaidya A, Sun B, Forman JP, Hopkins PN, Brown NJ, Kolatkar NS, Williams GH, Williams JS. The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians. Clinical Endocrinology 2011, 74: 783-790. PMID: 21521263, PMCID: PMC3089671, DOI: 10.1111/j.1365-2265.2011.03991.x.Peer-Reviewed Original ResearchConceptsPlasma renin activityVitamin D receptorLow plasma renin activityDietary sodium balanceRenin-angiotensin systemRenin activityFok1 polymorphismSodium balanceVitamin D receptor gene polymorphismsD receptor gene polymorphismsPopulation of hypertensivesReceptor gene polymorphismsFok1 genotypeHyperPATH cohortD deficiencyMultivariable analysisNormotensive individualsVitamin DRenin expressionVDR geneCardiovascular diseaseD receptorHuman studiesGene polymorphismsT alleleRenin gene polymorphism: its relationship to hypertension, renin levels and vascular responses
Sun B, Williams JS, Pojoga L, Chamarthi B, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Brown NJ, Ferri C, Williams GH. Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses. Journal Of The Renin-Angiotensin-Aldosterone System 2011, 12: 564-571. PMID: 21490026, PMCID: PMC3444254, DOI: 10.1177/1470320311405873.Peer-Reviewed Original ResearchConceptsMean arterial pressurePlasma renin activityRenin activityRenin geneHypertension riskSingle nucleotide polymorphismsAngiotensin II infusionNormotensive Caucasian subjectsHyperPATH cohortII infusionPRA levelsVascular responsivenessRenin levelsArterial pressureEssential hypertensionVascular responsesAngiotensin IIHypertensionHigh riskIndependent cohortCaucasian subjectsA alleleResultant haplotypesUnderlying mechanismGene variation
2010
The Relationship between Peroxisome Proliferator-Activated Receptor-γ and Renin: A Human Genetics Study
Underwood PC, Sun B, Williams JS, Pojoga LH, Chamarthi B, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, Williams GH. The Relationship between Peroxisome Proliferator-Activated Receptor-γ and Renin: A Human Genetics Study. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e75-e79. PMID: 20631015, PMCID: PMC2936061, DOI: 10.1210/jc.2010-0270.Peer-Reviewed Original ResearchConceptsPRA levelsPeroxisome proliferator-activated receptor gamma agonistPlasma renin activity levelsProliferator-activated receptor gamma agonistsVolume retentionAfrican-American hypertensivesHigh PRA levelsLow-salt dietRenin activity levelsAngiotensin II infusionMajor allele carriersSingle nucleotide polymorphismsC allele carrier statusReceptor gamma agonistsAllele carrier statusII infusionHypertensive participantsCombined P valueHuman hypertensionGamma agonistsNucleotide polymorphismsAllele carriersPPARgamma agonistsPPARgamma geneRenin